Itk Inhibitor

GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a K_i of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4⁺ T-cell proliferation, and inhibits activation-induced cell death of CD4⁺ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.

EGFR-IN-40 (compound 3z) is a potent BTK, EGFR, and ITK inhibitor with IC₅₀ values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.

PROTAC BTK Degrader-13 is a reagent targeting BTK, with a DC₅₀ of 0.27 μM. PROTAC BTK Degrader-13 degrades BTK in a proteasome-dependent manner and inhibits BTK-mediated downstream signaling pathways by reducing the phosphorylation levels of BTK and p38 MAPK. PROTAC BTK Degrader-13 exerts selective cytotoxic effects on BTK-overexpressing lymphoma cells and ITK-positive cells. PROTAC BTK Degrader-13 can be used in studies related to B-cell lymphoma.

Soquelitinib (Standard) is the analytical standard of Soquelitinib (HY-150298). This product is intended for research and analytical applications. Soquelitinib (CPI-818) is an orally active and highly selective covalent interleuK_in-2-inducible K_inase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytoK_ine product inhibition. Soquelitinib increases tumor infiltration of normal CD8⁺ cells that possess enhanced T effector function.

Vecabrutinib (Standard) is the analytical standard of Vecabrutinib (HY-109078). This product is intended for research and analytical applications. Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with K_d values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC₅₀ of 24 nM for ITK.

PF-06465469 (Standard) is the analytical standard of PF-06465469 (HY-108691). This product is intended for research and analytical applications. PF-06465469 is a covalent inhibitor of ITK with an IC₅₀ of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma.

BMS-509744 (Standard) is the analytical standard of BMS-509744 (HY-11092). This product is intended for research and analytical applications. BMS-509744 is a potent, selective and ATP competitive Itk inhibitor with an IC₅₀ of 19 nM.